Rafferty Asset Management
RUBY

Rafferty Asset Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Rafferty Asset Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-119,669
Closed -$1.16M – 1347
2021
Q4 		$1.16M Buy
119,669
+33,568
+39% +$465K 0.01% 810
2021
Q3 		$1.54M Sell
86,101
-8,413
-9% -$183K 0.01% 702
2021
Q2 		$2.31M Buy
+94,514
New +$2.36M 0.01% 649

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

Rafferty Asset Management's RUBY Position: Q1 2022 in Review

Rafferty Asset Management sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2022, closing a stake of 119,669 shares — an estimated $1.16M sold.

Rafferty Asset Management first reported a position in RUBY in Q2 2021 and held it in 3 quarters. The position peaked at $2.31M in Q2 2021. 117 funds tracked by Wall St. Rank hold RUBY as of Q1 2022.

  • Rafferty Asset Management reported no remaining Rubius Therapeutics, Inc position as of Q1 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 119,669 Rubius Therapeutics, Inc shares in Q1 2022, an estimated $1.16M.
  • Rafferty Asset Management first reported a position in Rubius Therapeutics, Inc in Q2 2021 and held it in 3 quarters.
  • Rafferty Asset Management's Rubius Therapeutics, Inc position peaked at $2.31M in Q2 2021.
  • 117 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2022.

Based on Rafferty Asset Management's 13F filing for Q1 2022, filed 13 May 2022.